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Objectives: To examine the effect of a combination of probiotics on the antibody response to pneumo-
coccal and pertussis vaccination in healthy Danish children, aged 8e14 months, at the time of starting
day care. Moreover, the cytokine response to lipopolysaccharide of whole blood was assessed.
Methods: A total of 290 children were randomly allocated to receive a combination of Biﬁdobacterium
animalis ssp. lactis and Lactobacillus rhamnosus GG daily for a 6-month intervention period, and blood
samples were drawn at the start and end of the study. Speciﬁc antibody response towards Streptococcus
pneumoniae serotypes and Bordetella pertussis toxin, as well as endotoxin-induced interleukin-6 (IL-6)
and interferon-g (IFN-g) production in blood were analysed by Luminex and ELISA.
Results: There was no signiﬁcant difference between the average individual changes from baseline to end
of study in antibody concentrations for S. pneumoniae for both the probiotics (340.4% ± 11.2%) and the
placebo group (382.9% ± 10.4%) (p 0.525), nor for B. pertussis toxin in the two groups (probiotics
190.1% ± 12.6% versus placebo 238.8% ± 1.1%, p 0.340). The average individual change in IL-6 concen-
tration was signiﬁcantly lower in the probiotics versus the placebo group (2.9% ± 10.3% versus
33.7% ± 9.0%, p 0.024), whereas there was no difference in IFN-g concentration (0.0% ± 0.2% versus
e0.2% ± 0.1%, p 0.279).
Conclusions: The probiotic intervention did not affect the antibody response against S. pneumoniae and
B. pertussis toxin in healthy Danish children. C. Adler Sørensen, Clin Microbiol Infect 2019;25:511.e1
e511.e7
© 2018 The Authors. Published by Elsevier Ltd on behalf of European Society of Clinical Microbiology and
Infectious Diseases. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Around 90% of all Danish children aged 1e2 years attend day
care [1]. These children have an increased risk of respiratory and
gastrointestinal infections compared with children in home-care
[2,3]. Especially the ﬁrst 6 months of enrolment into day care
have been associated with a high incidence of hospitalizations forf Bacteria, Parasites & Fungi,
hagen S, Denmark.
ually to the work.
Ltd on behalf of European Society
g/licenses/by-nc-nd/4.0/).acute respiratory infections [2]. Therefore, strategies to reduce and
prevent infections at this stage are of great importance.
The 13-valent pneumococcal conjugate vaccine (PCV13) was
introduced in the Danish Childhood Immunization Programme in
2010 [4]. The PCV13 has led to a 71% reduction in invasive pneu-
mococcal disease in Danish children <2 years old (considered as the
vaccine effectiveness) [4]. Vaccination against Bordetella pertussis is
an acellular vaccine of pertussis toxoid [5] and has a reported ef-
ﬁcacy of >70% [6]. It was suggested that the intestinal microbiota
may improve vaccine responses as dysbiosis resulted in systemic
inﬂammation and lower vaccine responses [7]. Likewise, probiotics
may facilitate stimulation of the host immune system. Studies and
meta-analyses have addressed the effects of probiotics on vaccineof Clinical Microbiology and Infectious Diseases. This is an open access article under
C. Adler Sørensen et al. / Clinical Microbiology and Infection 25 (2019) 511.e1e511.e7511.e2responses in both adults and children, and the results indicate a
variation in efﬁcacy of stimulating the immune system depending
on the use of probiotic strains, population and vaccination type
[8e10]. In the studies reported so far about half report a beneﬁcial
effect. As the studies, apart from the vaccine regimen, vary with
respect to type and number of strains, dose, intervention period,
age and group size, no clear conclusions of the effect of probiotics
on antibody response to vaccination is available. Similarly, there are
no indications of which childrenmay beneﬁt immunologically from
a probiotic intervention.
The ProbiComp study investigated the effect of a daily admin-
istration of a probiotic mixture, for 6 months to children from the
enrolment in day care at the age of 8e14months, on absence due to
infections [11]. As a secondary outcome, we here report the effects
of the probiotics on immunological responses to vaccine exposure
to PCV13 and to pertussis toxoid. In addition, as an alternative
measure of the probiotic effect on the humoral response, we
assessed the capability of cytokine production after ex vivo lipo-
polysaccharide (LPS) -stimulated whole blood.
Methods
Design and study population
This study was part of the ProbiComp study, a double-blind,
placebo-controlled parallel study described in detail by Laursen
et al. [11]. In short, 290 Danish children (8e14 months) were
randomly assigned to a combination of probiotics Lactobacillus
rhamnosusGG (LGG) and Biﬁdobacterium animalis ssp. lactis (BB-12)
at a dose of 2  109 CFUs or placebo (maltodextrin) each for a 6-
month period. LGG and BB-12 are registered trademarks of Chr.Table 1
Characteristics of study participants with blood samples from visits 1 and 2 (n ¼ 213)
Parameter Probiotics gro
Female, n (%) 47 (45.2)
Siblings, n (%) 56 (51.4)
Breastfeeding prevalence:
Visit 1, n (%) 51 (49)
Visit 2, n (%) 11 (10.6)
Indoor pets, n (%) 23 (22.1)
Daily smoking indoors, n (%) 1 (0.2)
Health status since birth:
Doctor-diagnosed asthma or allergic rhinitis, n (%) 0 (0)
Doctor-diagnosed atopic dermatitis, n (%) 10/20 (50)
Age:
Visit 1 (median months, IQR) 10 (9.4e10.4)
Start day care (median months, IQR) 10.3 (9.9e11.
Visit 2 (median months, IQR) 16.1 (15.6e16
Vaccination:
PCV13 coverage 1 at visit 1, n (%) 6 (5.8)
PCV13 coverage 2 at visit 1, n (%) 97 (93.3)
PCV13 coverage 2 at visit 2, n (%) 16 (15.4)
PCV13 coverage 3 at visit 2, n (%) 88 (87.6)
No PCV13 vaccinations 1 (1)
PT coverage 1 at visit 1, n (%) 6 (5.8)
PT coverage 2 at visit 1, n (%) 98 (94.2)
PT coverage 2 at visit 2, n (%) 15 (14.4)
PT coverage 3 at visit 2, n (%) 88 (84.6)
No PT vaccinations 1 (1)
No info visit 1 or visit 2 2 (1.9)
PCV13 vaccine before visit 1 (median days, IQR) 141 (123.2e1
PCV13 vaccine before visit 2 (median days, IQR) 105 (89e137
PT vaccine before visit 1 (median days, IQR) 141 (125e16
PT vaccine before visit 2 (median days, IQR) 105 (89e137
Compliance:
Second visit (median % of consumed probiotics, IQR) 97 (93e99)
IQR, interquartile range; PCV, pneumococcal conjugated vaccine; PT, pertussis toxin; Vis
a Pearson's chi-squared test.
b Welch two sample t-test.Hansen A/S. Recruitment was carried out for two seasons, from
mid-August to mid-December in 2014 and 2015. The children were
recruited from the National Danish Civil Registry by the principal
investigators of the ProbiComp study [11]. The probiotic and pla-
cebo powders were provided in identical sachets and did not differ
in smell, taste, or colour. Study personnel and parents were un-
aware of the nature of the product. The children were assigned to
receive either probiotics or a placebo by using block randomization
with a block size of eight and unblinding was performed only after
completion of data collection and statistical analyses. Children
underwent clinical examinations and blood samples were taken at
two visits, before the start of day care and entering intervention,
and after 6months, at the end of the intervention. The parents were
interviewed upon inclusion about household characteristics and
infant history of illness since birth.Vaccination data
In Denmark, pneumococcal conjugated vaccine (PCV13) and
vaccination against B. pertussis toxin (PT), are both administered at
3 months, 5 months and 12 months of age. At baseline, children
were at the ages 8e13 months and by end of the study their ages
were 14e19 months. Vaccination data were also obtained for each
participating child to assess the time between last given vaccina-
tion and blood sampling time. Vaccination datawere obtained from
the Danish Vaccination Register. Vaccination coverage of partici-
pating children are presented in Table 1.up (n ¼ 104) Placebo group (n ¼ 109) p value
53 (48.6) 0.616a
53 (48.6) 0.446a
48 (44) 0.464a
8 (7.3) 0.407a
23 (21.1) 0.857a
0 (0) 0.305a
0 (0) 1.000
8/21 (38.1) 0.443a
10.1 (9.6e10.5) 0.347b
2) 10.4 (10e11.2) 0.428b
.5) 16.0 (15.6e16.6) 0.527b
9 (8.3) 0.490a
100 (91.7) 0.490a
12 (11) 0.345a
97 (89) 0.345a
0 (0) 0.305a
7 (6.4) 0.842a
102 (93.6) 0.088a
12 (11) 0.954a
97 (89) 0.438a
0 (0) 0.303a
0(0) 0.146a
59.2) 141 (126.8e160) 0.858b
.2) 104 (80e126) 0.093b
0) 141.9 (126.8e229) 0.509b
) 108.5 (80e126) 0.073b
97 (94e99) 0.987b
it 1, baseline at inclusion; Visit 2, end-point at end of study.
C. Adler Sørensen et al. / Clinical Microbiology and Infection 25 (2019) 511.e1e511.e7 511.e3Blood sampling and sample preparation
Peripheral whole blood was drawn at baseline and end of study,
and aliquots (approx. 0.5 mL) were subsequently sampled accord-
ing to the type of analysis. Serumwas collected and stored ate80C
until examination by Luminex and ELISA. For LPS stimulation of
whole blood, freshly drawn blood was used within 30 min.
Antibody measurements of S. pneumoniae serotypes and B. pertussis
toxin
Antibody measurements against speciﬁc anti-pneumococcal
capsular IgG (IgG-PN) were performed for 12 S. pneumoniae sero-
types: 1, 3, 4, 5, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F, using a
Luminex-based assay previously described by Kantsø et al. [12]. The
geometric mean of the antibody measurements against the 12 se-
rotypes was used for analysis and all ‘out of range’ high values were
set to 50 mg/L for all calculations.
IgG antibodies to B. pertussis toxin (IgG-PT) were measured by
an ELISA previously described by Dalby et al. [13,14]. Results were
expressed as IU/mL according to the WHO International Standard
Pertussis Antiserum National Institute for Biological Standards and
Control code 06/140.
Interleukin-6 and interferon-g production in LPS-stimulated whole
blood
Freshly drawn whole blood was stimulated essentially as pre-
viously described [15]. In brief, duplicates of 50 mL EDTA-treated
whole-blood were diluted in 450 mL RPMI-1640 medium, stimu-
lated with 1 mg/L LPS from Escherichia coli O26:B6 (Sigma Aldrich,
St Louis, MO, USA), and incubated at 37C and 5% CO2 for 24 h.
Interleukin-6 (IL-6) and interferon-g (IFN-g) concentration in the
supernatants were measured by sandwich-ELISA using antibody
pairs (R&D Systems, Minneapolis, MN, USA). The detection limits
for the IL-6 and IFN-g assays were 147 ng/L and 15 ng/L, respec-
tively, and intra- and inter-assay coefﬁcient of variation were 14%
and 8% for IL-6 and 18% and 4% for IFN-g, respectively.
Ethical considerations
The protocol for the study was approved by the Committees on
Biomedical Research Ethics for the Capital Region of Denmark (H-4-
2014-032). Furthermore, the study was registered at clinicaltrials.
gov (identiﬁer NCT02180581 posted 2 July 2014). This study
required informed consent from parents and legal guardians of the
children. Participation in the study was voluntary and parents
could withdraw their consent at any time [11]. Vaccination data
were obtained at the Danish Vaccination Register (record number
2015-57-0102).
Statistics
Baseline characteristics are shown as the mean (SD) or median
(interquartile range (IQR)) for continuous variables and n (%) for
categorical variables, and difference between the probiotics and
placebo groups was evaluated by Pearson's chi-squared test or
Welch two-sample t-test. The effect of probiotics on the change
from baseline to end of study was evaluated by using mixed linear
models with simultaneous tests for general linear hypothesis.
Changes from baseline to end of study and differences between
treatment groups at baseline or end of study were tested by
selected pairwise comparisons. Due to the logarithmic nature of
antibody titre data, the % change from baseline to end of study and% difference between treatment groups were calculated from the
estimate given by R using the formula (exp(Estimate)e 1)*100, and
the SD was similarly calculated from the standard error given by R
using the formula (exp(standard error)e 1)*100. Both % change and
% difference and their corresponding SD values for cytokine re-
sponses were directly provided by R. Only children with blood
samples available for both visits were included in the analyses. All
statistical analyses were performed in the software R (version 3.4.3;
R Core Team, 2017. R: a language and environment for statistical
computing. R Foundation for Statistical Computing, Vienna,
Austria), using the LME4 package.
Results
Study population
In total, 260 of the 290 children completed the study (Fig. 1, see
ref. [11] for more details). It was possible to collect blood from 252
children at intervention start and 231 children at end of study, and
213 children delivered blood samples at both visits. The aliquot
volume of collected blood was, however, not always sufﬁcient,
limiting the analyses to be made. The numbers of analyses are
shown in Fig. 1.
The probiotic and placebo groups had similar distributions
regarding sociodemographic factors, duration of breastfeeding,
health status since birth, time between sampling and vaccinations,
and study compliance (Table 1).
Antibody response towards S. pneumoniae and B. pertussis
vaccination
We assessed the geometric mean of the antibody concentrations
against 12 S. pneumoniae serotypes for a total of 160 children and
measured human IgG antibodies against PT in serum samples from
152 children.
No signiﬁcant difference was observed in the S. pneumoniae
antibody response measured between the group of children given
probiotics and placebo, neither at baseline nor end of study
(Table 2). The antibody concentrations measured at end of study
(probiotics 5.18 mg/L, IQR 2.15e9.26 and placebo 5.62 mg/L, IQR
2.35e11.91) were signiﬁcantly higher than baseline concentrations
(probiotics 1.11 mg/L, IQR 0.58e1.68 and placebo 1.02 mg/L, IQR
0.72e1.81, p 0.001) (Table 2). However, there was no difference in
the change from baseline to end of study in antibody response
between the treatment groups (p 0.525) (Table 2, see Supplemen-
tary material, Fig. S1). Also, the time (measured in days) since last
vaccination at both baseline and end of study signiﬁcantly affected
the concentrations (at baseline a decrease of 0.95%/day; at end of
study a decrease of 0.97%/day, p  0.001) (see Supplementary
material, Fig. S2).
Likewise, there was no signiﬁcant difference in the PT antibody
response measured between the group of children given probiotics
and placebo, neither at baseline nor end of study (Table 2). The
concentrations of PT antibodies were signiﬁcantly different from
baseline to end of study. In the probiotic group, the antibody con-
centrations measured at end of study (57.29 IU/mL, IQR
35.30e101.67) were signiﬁcantly higher than baseline concentra-
tions (19.46 IU/mL, IQR 11.09e33.53, p  0.001) (Table 2). In the
placebo group, the antibody concentrations measured at end of
study (57.87 IU/mL, IQR 32.27e101.99) were signiﬁcantly higher
than baseline concentrations (17.64 IU/mL, IQR 9.55e30.64,
p  0.001) (Table 2). There was no difference in the change from
baseline to end of study in antibody response between the treat-
ment groups (p 0.340) (Table 2, see Supplementary material,
Table 2
Antibody response towards vaccination
Streptococcus pneumoniae (IgG-PNGM mg/L)
(n ¼ 160)
Bordetella pertussis toxin (IgG-PT IU/mL)
(n ¼ 152)
Baseline
median (IQR)
End of study
median (IQR)
Change % p value Baseline
median (IQR)
End of study
median (IQR)
Change % p value
Probiotic group
(n ¼ 74)
1.11 (0.58e1.68) 5.18 (2.15e9.26) 340.4 0.001a Probiotic group
(n ¼ 70)
19.46 (11.09e33.53) 57.29 (35.30e101.67) 190.1 0.001a
Placebo group
(n ¼ 86)
1.02 (0.72e1.81) 5.62 (2.35e11.91) 382.9 0.001a Placebo group
(n ¼ 82)
17.64 (9.55e30.64) 57.87 (32.27e101.99) 238.8 0.001a
Difference % 4.6 e14.7 Difference % 13.4 e1.2
p value 0.988a 0.749a 0.525b p value 0.727a 1.000a 0.340b
IQR, interquartile range.
a Mixed linear model with selected pairwise comparisons.
b Mixed linear model with simultaneous tests for general linear hypothesis.
Fig. 1. Flowchart of participants and number of blood samples analysed.
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baseline and end of study depended on the time (measured in days)
since last vaccination (at baseline decrease of 0.75%/day and at end
of study 0.63%/day, p 0.001 (see Supplementary material, Fig. S2).Whole blood LPS-stimulation-induced IL-6 and IFN-g responses
Concentrations of IL-6 changed from baseline (6139 ng/mL, IQR
2840e9625) to end of study (9798 ng/mL, IQR 5547e12 322) in
Table 3
Lipopolysaccharide-induced cytokine responses in whole blood
Interleukin-6 (ng/mL)
(n ¼ 118)
Interferon-g (ng/mL)
(n ¼ 96)
Baseline
median (IQR)
End of study
median (IQR)
Change % p value Baseline
median (IQR)
End of study
median (IQR)
Change % p value
Probiotic group
(n ¼ 51)
8234 (3078e12055) 8278 (3276e9625) 2.9 0.993a Probiotic group
(n ¼ 41)
41.88 (6.00e95.00) 56.00 (15.67e87.33) 0.0 1.000a
Placebo group
(n ¼ 67)
6139 (2840e9625) 9798 (5547e12322) 33.7 0.001a Placebo group
(n ¼ 55)
42.00 (6.05e106.17) 55.33 (19.33e80.67) e0.2 0.383a
Difference % e12.2 18.7 Difference % e0.2 0.1
p value 0.616a 0.235a 0.0238b p value 0.728a 0.979a 0.279b
IQR, interquartile range.
a Mixed linear model with selected pairwise comparisons.
b Mixed linear model with simultaneous tests for general linear hypothesis.
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p  0.001) (Table 3). No change from baseline (8234 ng/mL, IQR
3078e12 055) to end of study (8278 ng/mL, IQR 3276e9625) was
observed in the probiotics group (2.85% ± 10.27%, p 0.993) (Table 3).
This resulted in an overall signiﬁcant difference in the change in
LPS-stimulated IL-6 concentration from baseline to end of study
between treatment groups (p 0.0238) In contrast, there was no
difference in the change of LPS-stimulated IFN-g production from
baseline to end of study between the two groups (p 0.279) (Table 3,
see Supplementary material, Fig. S3). Speciﬁcally, concentrations of
IFN-g changed from baseline (42.00 ng/mL, IQR 6.05e106.17) to end
of study (55.33 ng/mL, IQR 19.33e80.67) in LPS-stimulated whole
blood in the placebo group (e0.23% ± 0.14%, p 0.383) (Table 3). No
change from baseline (41.88 ng/mL, IQR 6.00e95.00) to end of
study (56.00 ng/mL, IQR 15.67e87.33) was observed in the pro-
biotics group (0.01% ± 0.17%, p 1.000) (Table 3).
Discussion
We have assessed the effect of a daily intake of a combination of
probiotic strains, LGG and BB-12, on the response to vaccinations
against S. pneumoniae and B. pertussis in healthy children starting in
day care as a secondary outcome of the ProbiComp study [11]. It
was previously shown that the administered probiotic strains could
be detected in faeces and proliferated in the gut, but did not change
the gut microbiota community structure [16]. In this study, we did
not ﬁnd an effect on the concentration of speciﬁc antibody
response between the probiotic and placebo group towards the two
vaccines. Yet, the vaccine response was high (Table 2). Moreover, to
study a systemic effect of the probiotics, we also assessed changes
in the capability to produce cytokines upon ex vivo LPS stimulation
in whole blood and found here signiﬁcant difference between the
IL-6 production in blood from the group receiving probiotics and
the placebo group.
Only a limited number of other studies have assessed the effect
of probiotics on the outcome of vaccination in children. To our
knowledge, seven other studies have addressed the effect of pro-
biotics on the antibody response against toxoid vaccines and car-
bohydrate vaccines in children/infants. They vary greatly in number
of participants, duration, and dose and strains of administered
probiotics. Of these, three studies administered probiotics to in-
fants from birth in a period of 4e12 months [17e19]. One study
assessed the effect of administering a probiotic mixture of around
1.2 1010 CFU daily to newborn infants during the ﬁrst 6 months of
life. Antibody titres against diphtheria and tetanus toxoid in the 6-
month-old children showed no signiﬁcant differences between the
probiotic and placebo group, but for Haemophilus inﬂuenzae type B,
concentrations tended to be higher in the probiotic group [17]. The
same trend ofHaemophilus inﬂuenzae type B IgG level was observedin another study [18]. A recent study also did not ﬁnd any differ-
ences after probiotic supplementation in diphtheria, tetanus,
pertussis, polio and hepatitis B antibody titres [19].
Four studies initiated the probiotic intervention at a later time-
point, between 2 months and 5 years [20e23]. Of these studies, the
study by Perez et al. [21] is most comparable with ours, as they also
addressed the IgG response to pneumococcal vaccination and saw
no effect of the probiotic intervention. However, in contrast to our
study, the enrolled children varied greatly in age (from 9 months to
10 years), and were from families of low socio-economic status and
presumed to have been exposed to a high microbial load. Such
factors are expected to affect the study outcome, e.g. by higher
variation due to time since last vaccination, or by reducing the ef-
fect of the probiotic intervention due to the high microbial load.
Even though the children in the present study came from families
in Denmark where the majority of parents had >15 years of edu-
cation, so indicating a ‘high hygienic lifestyle’, no effect of the
probiotic intervention was found. Hence, the importance of the
microbial stimulation for the strength of the antibody response
towards these types of vaccines is questionable. Of note, in our
study the probiotic intervention took place during the ﬁrst months
in day care, a time where the infant encounters a high number of
microorganisms of high diversity, and so maydwith respect to the
microbial loaddnot differ substantially from the Perez et al. study
[21]. Taken together, our study is in line with former studies, which
found no or few trends towards an increase in antibody levels to-
wards the injected antigens (notably against Haemophilus inﬂuen-
zae type B).
We also performed another analysis of systemic blood param-
eters; cytokine production (IL-6 and IFN-g) upon ex vivo LPS-
stimulated whole blood. The production of IL-6 by whole blood
reﬂects the number and response of innate leucocytes, notably
monocytes, while IFN-g is produced by natural killer cells and T
helper type 1 cells [24,25]. Here, we found that the change in IL-6
level differed signiﬁcantly between the probiotic and placebo
groups. This may imply that probiotics may affect the capability to
respond to a microbial stimulus or LPS. However, as the difference
seems to be greatly driven by a lower IL-6 baseline level in the
placebo group, we cannot rule out that the difference is due to
regression to the mean in the placebo group.
Number of probiotic bacteria as well as the strain(s) used seems
to inﬂuence the outcome [10]. In our study, the dose was
2  109 CFU/day, which is comparable to most other infant studies.
The combination of LGG and BB-12 has not been used in any of the
reported studies, hence we cannot exclude that other strains would
have given a different outcome.
Most of the studies showing an enhancing effect of the antibody
titre enrolled individuals above 65 years [26], indicating that a
positive effect of probiotics may depend on the immune status of
C. Adler Sørensen et al. / Clinical Microbiology and Infection 25 (2019) 511.e1e511.e7511.e6the participants, as it is well-known that the immune system de-
teriorates with age. As the effects of probiotics on vaccination are
mostly seen in studies involving elderly individuals, this points
towards the fact that vaccines today are so efﬁcient that an effect of
probiotics is merely on the general status of the immune system.
Hence, we suggest that immunocompromised individuals and
elderly will beneﬁt from probiotics by improved protection upon
vaccination.
A strength in the current study is that blood samples were
drawn at enrolment as well as at the termination of the interven-
tion, allowing us to baseline adjust end-point values. A limitation in
the study is that we did not test against viral vaccines (rubella,
mumps, measles), which might have given another outcome.
However, in other studies children did not showmarkedly different
outcome of probiotic intervention on the viral vaccines compared
with the toxoid and carbohydrate vaccines [10,19]. We studied the
effects of probiotics in healthy Danish children assumed to have a
well-developed immune system. A group of immunocompromised
children might have given other results.
The prevailing theories regarding the mechanism(s) by which
probiotics exert their putativeeffects are still debated. In general, the
probiotic bacteria are believed to, like other bacteria, stimulate the
innate immune system but may also affect the polarization of the
adaptive immune system [27]. We have recently shown that pro-
biotics administered to newborn mice with a depleted microbiota
increased granulopoiesis (unpublisheddata), amechanism thatmay
explain a positive effect of probiotics on inﬂuenza-vaccinated
elderly. This mechanism may also explain the signiﬁcant differ-
ence in ex vivo IL-6 production in LPS-stimulated whole blood, as a
high concentration of neutrophils in blood may affect the concen-
tration of monocytes, the main IL-6 producers in blood. This is,
however, purely speculative because we cannot rule out the possi-
bility of regression to themean in the placebo group. Probioticsmay
also aid the stimulation of defence mechanisms in the epithelium,
notably production of mucins and anti-microbial peptides. This
mechanismmay explainwhymore pronounced effects are found in
studies of probiotics and mucosal vaccines [28,29].
In conclusion, we did not ﬁnd an effect of probiotic intervention
on the antibody titres to pneumococcal and pertussis toxoid
vaccination in 14- to 18-month-old children after their ﬁrst months
in day care. This may reﬂect how efﬁcient the vaccines are and
suggests that only immunocompromised individuals and elderly
may beneﬁt from probiotics to strengthen the outcome of
vaccination.
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